Fanos Vassilios, Marcialis Maria Antonietta, Bassareo Pier Paolo, Antonucci Roberto, Zaffanello Marco, Dessì Angelica, Iacovidou Nicoletta
Department of Pediatrics and Clinical Medicine, Section of Neonatal Intensive Care Unit, Puericulture Institute and Neonatal Section, Azienda Mista and University of Cagliari, Cagliari, Italy.
J Matern Fetal Neonatal Med. 2011 Oct;24 Suppl 1:50-2. doi: 10.3109/14767058.2011.607593.
Patent ductus arteriosus (PDA) often complicates the clinical course of neonates born prematurely and increases their short- and long-term morbidity. Treatment of PDA remains an ongoing debate among neonatologists for various issues such as the timing, the criteria and the methods for its closure. Non steroidal anti inflammatory drugs have been used as the standard pharmacological treatment for PDA. Indomethacin was the first one to be used. Its use though, waned due recognition of renal cerebral and gastrointestinal complications associated with the administration of this drug. Ibuprofen has emerged in clinical practice, as it has been reported to have lower nephrotoxicity. This review will examine existing data in the literature on the early- and long-term nephrotoxicity associated with the two drugs and will discuss present and future directions the management and prevention of this condition.
动脉导管未闭（PDA）常使早产儿的临床病程复杂化，并增加其短期和长期发病率。对于PDA的治疗，新生儿科医生围绕诸如关闭的时机、标准和方法等各种问题仍存在持续的争论。非甾体类抗炎药一直被用作PDA的标准药物治疗。吲哚美辛是最早使用的药物。然而，由于认识到与该药物给药相关的肾、脑和胃肠道并发症，其使用逐渐减少。布洛芬已出现在临床实践中，因为据报道它具有较低的肾毒性。本综述将研究文献中关于这两种药物相关的早期和长期肾毒性的现有数据，并将讨论这种情况的管理和预防的当前及未来方向。
